{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-24-000038","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.652376+00:00","generated_at":"2026-06-05T01:32:11.945249+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evolus reports record Q4 revenue $61.0M (+40% YoY); guides to Q4 2024 profitability","bullets":["Full-year 2023 net revenue $202.1M (+36% YoY); Q4 record $61.0M (+40% YoY).","Q4 non-GAAP operating loss narrowed to $3.7M from $5.7M in Q3; full-year non-GAAP loss down 48% to $23.4M.","Reaffirms 2024 revenue guidance $255-265M (26-31% growth); expects positive non-GAAP operating income in Q4 2024 and full year 2025.","Added 840+ new Jeuveau accounts in Q4, total >12,400; loyalty program grew 55% to 750,000 members.","Plans to file PMA for first two Evolysse fillers by mid-2024; targets at least $700M net revenue by 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-24-000038","json":"https://secwatch.observer/filing/0001570562-24-000038.json","markdown":"https://secwatch.observer/filing/0001570562-24-000038.md","text":"https://secwatch.observer/filing/0001570562-24-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000038/0001570562-24-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000038/eols-20240307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:32:11.945249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f526b98844f73a015eb078dc5ff6457e5f38e5e","claim":"Evolus, Inc. reported the quarter and year ended December 31, 2023 results: revenue $61.0 million. Guidance reaffirmed.","evidence_excerpt":"of $2 Million Compared to Q3 • Full-Year 2023 Operating Expense of $163.9 Million in Alignment with Guidance Range of $160 Million to $165 Million • Global Net Revenue Record of $61.0 Million for the Fourth Quarter and $202.1 Million Full-Year 2023, Representing 40% and 36% Growth Over the Prior Year; These Results Are Unchanged from the Preliminary Results Reported","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000038/0001570562-24-000038-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$61.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}